

7. References

- [1] Goh CF, Lane ME. Formulation of diclofenac for dermal delivery. *Int J Pharm.* 2014;473(1-2):607-16.
- [2] van Es JH, Giles RH, Clevers HC. The many faces of the tumor suppressor gene APC. *Exp Cell Res.* 2001;264(1):126-34.
- [3] Dasari S, Wudayagiri R, Valluru L. Cervical cancer: Biomarkers for diagnosis and treatment. *Clin Chim Acta.* 2015;445:7-11.
- [4] Valle BL, D'Souza T, Becker KG, Wood WH 3rd, Zhang Y, Wersto RP, et al. Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. *PLoS One.* 2013;8(4):e61836.
- [5] Marques JG, Gaspar VM, Costa E, Paquete CM, Correia IJ. Synthesis and characterization of micelles as carriers of non-steroidal anti-inflammatory drugs (NSAID) for application in breast cancer therapy. *Colloids Surf B Biointerfaces.* 2014;113:375-83. 26.
- [6] Kaur J, Sanyal SN. Intrinsic mitochondrial membrane potential change and associated events mediate apoptosis in chemopreventive effect of diclofenac in colon cancer. *Oncol Res.* 2010;18(10):481-92.
- [7] Frantzias J, Logan JG, Mollat P, Sparatore A, Del Soldato P, Ralston SH, et al. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. *Br J Pharmacol.* 2012;165(6):1914-1925.
- [8] Zerbini LF, Tamura RE, Correa RG, Czibere A, Cordeiro J, Bhasin M, et al. Combinatorial effect of non-steroidal anti-inflammatory drugs and NF- κ B inhibitors in ovarian cancer therapy. *PLoS One.* 2011;6(9):e24285.
- [9] Doat S, C  n  e S, Tr  tarre B, Rebillard X, Lamy PJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. *Cancer Med.* 2017;6(10):2461-2470.
- [10] Daniels NA, Chen YH, Bent S. Antibiotic and anti-inflammatory use and the risk of prostate cancer. *BMC Res Notes.* 2009;2:57.
- [11] Friel G, Liu CS, Kolomeyevskaya NV, Hampras SS, Kruszka B, Schmitt K, et al. Aspirin and Acetaminophen Use and the Risk of Cervical Cancer. *J Low Genit Tract Dis.* 2015;19(3):189-93.
- [12] Narayan S, Jaiswal AS, Law BK, Kamal MA, Sharma AK, Hromas RA. Interaction between APC and Fen1 during breast carcinogenesis. *DNA Repair (Amst).* 2016;41:54-62
- [13] Chen TH, Chang SW, Huang CC, Wang KL, Yeh KT, Liu CN, et al. The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer. *Colorectal Dis.* 2013;15(11):1367-74.
- [14] Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. *Ann Oncol.* 2013;24(3):693-701
- [15] Olsen AK, Coskun M, Bzorek M, Kristensen MH, Danielsen ET, J  rgensen S. et al. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. *Carcinogenesis.* 2013;34(6):1361-9.
- [16] Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. *Cancer Chemother Pharmacol.* 2009;63(4):605-13.